Cargando…

An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy

Facioscapulohumeral muscular dystrophy (FSHD) is an incurable myopathy linked to the over-expression of the myotoxic transcription factor DUX4. Targeting DUX4 is the leading therapeutic approach, however, it is only detectable in 0.1–3.8% of FSHD myonuclei. How rare DUX4 drives FSHD and the optimal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cowley, Matthew V, Pruller, Johanna, Ganassi, Massimo, Zammit, Peter S, Banerji, Christopher RS
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2023
Materias:	Cell Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287159/ https://www.ncbi.nlm.nih.gov/pubmed/37184373 http://dx.doi.org/10.7554/eLife.88345

Ejemplares similares

DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation
por: Banerji, Christopher R S, et al.
Publicado: (2020)

Antagonism Between DUX4 and DUX4c Highlights a Pathomechanism Operating Through β-Catenin in Facioscapulohumeral Muscular Dystrophy
por: Ganassi, Massimo, et al.
Publicado: (2022)

PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level
por: Banerji, Christopher R S, et al.
Publicado: (2019)

Therapeutic Strategies Targeting DUX4 in FSHD
por: Le Gall, Laura, et al.
Publicado: (2020)

Functional domains of the FSHD-associated DUX4 protein
por: Mitsuhashi, Hiroaki, et al.
Publicado: (2018)

DUX4 Binding to Retroelements Creates Promoters That Are Active in FSHD Muscle and Testis
por: Young, Janet M., et al.
Publicado: (2013)

DUX4 Expression in FSHD Muscles: Focus on Its mRNA Regulation
por: Sidlauskaite, Eva, et al.
Publicado: (2020)

The FSHD Atrophic Myotube Phenotype Is Caused by DUX4 Expression
por: Vanderplanck, Céline, et al.
Publicado: (2011)

Culture Conditions Affect Expression of DUX4 in FSHD Myoblasts
por: Pandey, Sachchida Nand, et al.
Publicado: (2015)

DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy
por: Mocciaro, Emanuele, et al.
Publicado: (2021)

Designed U7 snRNAs inhibit DUX4 expression and improve FSHD-associated outcomes in DUX4 overexpressing cells and FSHD patient myotubes
por: Rashnonejad, Afrooz, et al.
Publicado: (2020)

Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy
por: Moyle, Louise A, et al.
Publicado: (2016)

Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model
por: Lu-Nguyen, Ngoc, et al.
Publicado: (2021)

Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model
por: Bosnakovski, Darko, et al.
Publicado: (2017)

MATR3 is an endogenous inhibitor of DUX4 in FSHD muscular dystrophy
por: Runfola, Valeria, et al.
Publicado: (2023)

Proximity ligation assay to detect DUX4 protein in FSHD1 muscle: a pilot study
por: Beermann, Mary Lou, et al.
Publicado: (2022)

Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD?
por: Joubert, Romains, et al.
Publicado: (2020)

Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7
por: Banerji, Christopher R S, et al.
Publicado: (2021)

DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?
por: Tassin, Alexandra, et al.
Publicado: (2013)

Author Correction: Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model
por: Bosnakovski, Darko, et al.
Publicado: (2018)

Biphasic Myopathic Phenotype of Mouse DUX, an ORF within Conserved FSHD-Related Repeats
por: Bosnakovski, Darko, et al.
Publicado: (2009)

PARP1 Differentially Interacts with Promoter region of DUX4 Gene in FSHD Myoblasts
por: Sharma, Vishakha, et al.
Publicado: (2016)

DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD
por: Klingler, Christian, et al.
Publicado: (2020)

The FSHD muscle–blood biomarker: a circulating transcriptomic biomarker for clinical severity in facioscapulohumeral muscular dystrophy
por: Banerji, Christopher R S, et al.
Publicado: (2023)

Telomere Position Effect (TPE) Regulates DUX4 in Human Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Stadler, Guido, et al.
Publicado: (2013)

Expression of FSHD-related DUX4-FL alters proteostasis and induces TDP-43 aggregation
por: Homma, Sachiko, et al.
Publicado: (2015)

WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy
por: Mocciaro, Emanuele, et al.
Publicado: (2023)

DUX4c Is Up-Regulated in FSHD. It Induces the MYF5 Protein and Human Myoblast Proliferation
por: Ansseau, Eugénie, et al.
Publicado: (2009)

Nuclear bodies reorganize during myogenesis in vitro and are differentially disrupted by expression of FSHD-associated DUX4
por: Homma, Sachiko, et al.
Publicado: (2016)

Correction: A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy
por: Pruller, Johanna, et al.
Publicado: (2020)

A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy
por: Pruller, Johanna, et al.
Publicado: (2020)

Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
por: Sarsons, Christopher D., et al.
Publicado: (2023)

BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells
por: Campbell, Amy E., et al.
Publicado: (2017)

Myogenin is an essential regulator of adult myofibre growth and muscle stem cell homeostasis
por: Ganassi, Massimo, et al.
Publicado: (2020)

Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Jones, Takako I., et al.
Publicado: (2016)

Muscle Fiber Conduction Velocity Correlates With the Age at Onset in Mild FSHD Cases
por: Beretta-Piccoli, Matteo, et al.
Publicado: (2021)

Interplay between mitochondrial reactive oxygen species, oxidative stress and hypoxic adaptation in facioscapulohumeral muscular dystrophy: Metabolic stress as potential therapeutic target
por: Heher, Philipp, et al.
Publicado: (2022)

Asymmetric Bidirectional Transcription from the FSHD-Causing D4Z4 Array Modulates DUX4 Production
por: Block, Gregory J., et al.
Publicado: (2012)

Targeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic DUX4-fl expression in FSHD
por: Himeda, Charis L., et al.
Publicado: (2020)

Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD)
por: Ansseau, Eugénie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ffk1vtg6bu8av1vo2dtvinhjel